In the biological timeline of wound recovery, the inflammatory phase is not merely a symptom of injury but a necessary prerequisite for physiological healing. Under normal conditions, this phase dominates the first four days. However, when the inflammatory response becomes disproportionate in intensity or duration, the wound crosses an “inflammatory bridge” into a state of pathological stagnation.
A central concept in modern wound research is “Critical Colonization.” This represents the clinical transition point between physiological healing and pathological stagnation, where microbial proliferation occurs without classical signs of infection but results in delayed healing due to toxin production and the presence of resistant strains.
1. The Cellular Orchestration of Normal Inflammation
Physiological inflammation is a highly coordinated effort involving specific cellular and chemical actors. When this orchestration is balanced, the wound transitions seamlessly into the proliferative phase.
- Granulocytes (Neutrophils) and H_2O_2: As part of the non-specific immune response, neutrophils produce endogenous hydrogen peroxide (H_2O_2) to combat pathogens. It is clinically vital to distinguish this from the external application of pure H_2O_2, which is now considered obsolete because it inhibits fibroblasts and mammalian cells at concentrations as low as 8.5 mg/L. This obsolescence does not apply to endogenous H_2O_2 or the non-cytotoxic concentrations formed in medical honey (via glucose oxidase), which remain vital to the immune cascade.
- Macrophages and Growth Factors: Macrophages are the primary drivers of the transition out of inflammation. They facilitate the release of Platelet-Derived Growth Factor (PDGF). Modern antiseptics like Octenidine (OCT) support this process by stimulating growth factors and phagocytosis, whereas agents like Chlorhexidine (CHD) show higher cytotoxicity.
- Cytokines and Inflammation Mediators: The regulation of cytokines is paramount to preventing hyper-inflammation. Stabilization of cell membranes inhibits the excessive release of cytokines (e.g., from mast cells). Effective intervention aims to prevent the “low-grade” infection that triggers a self-perpetuating inflammatory cycle.
- Matrix Metalloproteinases (MMPs) and Tissue Destruction: Excessive mediator release and bacterial exotoxins trigger the production of tissue-destroying enzymes, specifically MMPs and elastase. This enzymatic surge causes structural tissue destruction, fueling wound stagnation. Interventions like Polyvinylpyrrolidone-iodine (PVP-I) or Polihexanide (PHMB) are utilized to inactivate these enzymes; specifically, PHMB inhibits the expression of elastase, protecting the wound bed.
2. Defining the Pathological Shift: Microbial Status
The transition from a healing wound to a stagnant one is defined by the microbial status and the resulting host response.
| Term | Microbial Characteristics | Host Reaction / Healing Impact |
| Contamination | Microorganisms are present and attached to the tissue. | No initial proliferation; no host reaction. |
| Colonization | Microorganisms are present and proliferating. | Lacks a clinically significant immunological host reaction. |
| Critical Colonization | Proliferation occurs without classical signs of infection. | Delayed healing due to toxin production or antibiotic-resistant strains. |
| Local Infection | Pathogenic proliferation with observable immunological response. | Stagnation in wound healing; typical clinical signs of infection present. |
3. Clinical Manifestations of Prolonged Inflammation
When a wound shifts into a pathological state, specific local signs emerge. Precise measurement is required for accurate diagnosis:
- Erythema: Redness extending 1–2 cm from the wound margin, often with a tendency to spread or increase.
- Edema: Localized swelling of the wound site and immediate vicinity.
- Exudate Changes: An increase in both the quantity and the viscosity of wound fluid.
- Thermic Shift: Perceptible increase in local skin or tissue temperature.
- Secondary Signs: The presence of a perceptible odor and functional impairment of the affected area.
- Stagnation: A complete lack of progress in wound dimensions.
4. Factors Prolonging the Inflammatory State: The WAR Score
The persistence of inflammation is quantified by the Wounds-at-Risk (WAR) Score. If the sum of points reaches or exceeds 3, antiseptic treatment is clinically indicated.
1 Point (Per Condition)
- Patient Factors: Acquired immunosuppressive disease (e.g., Diabetes mellitus), medical therapies (glucocorticoids, methotrexate, antibodies), or age >80 years.
- Wound Characteristics: Wounds persisting >1 year, dimensions >10 cm², or depth >1.5 cm.
- Environmental Factors: Potentially heavily contaminated areas (perineum, genitals) or problematic hygiene (social/occupational).
2 Points (Per Condition)
- Severe Immune Defects: E.g., HIV infection.
- Contamination: Heavily contaminated acute wounds.
- Moderate Trauma: Bite, stab, or gunshot wounds penetrating 1.5–3.5 cm.
3 Points (Per Condition)
- Critical Immunodeficiency: Stem cell transplantation, AIDS, or Wiskott-Aldrich syndrome.
- Extreme Trauma: Burn wounds >15% BSA, bite/stab/gunshot wounds >3.5 cm, or wounds containing foreign material.
- Structural Risks: Wounds connected to organs, joints, or functional structures.
5. Strategy for Resolution: The Role of Antisepsis
To break the cycle of prolonged inflammation and biofilm-mediated toxicity, clinicians must implement a targeted antiseptic strategy.
- Cleansing, Debridement, and Biofilm Management: Antiseptics are ineffective without the mechanical removal of debris. Biofilm removal is a prerequisite for success; agents such as OCT, PHMB, and Acetic Acid (AA) have demonstrated efficacy against established biofilms.
- The Biocompatibility Index (BI): The BI is the quotient of an agent’s bactericidal efficacy versus its toxicity to human fibroblasts. A BI > 1.0 indicates the agent is more toxic to bacteria than to human cells.
- OCT: BI 1.7–2.1 (Superior tolerability)
- PHMB: BI 1.4–1.5 (High tolerability; acts as a “detoxified CHD” without the carcinogenic 4-chloroaniline risk)
- PVP-I: BI 0.9–1.0
- CHD: BI 0.7 (More toxic to human cells than bacteria)
- Targeted Interventions:
- PHMB: Known for its intracellular elimination of pathogens (e.g., MRSA) and its ability to increase capillary density.
- Octenidine (OCT): Preferred for decolonization of MDRO-infected wounds.
- Acetic Acid (AA): A promising prospect specifically for its efficacy against P. aeruginosa, particularly in resource-limited settings.
6. Conclusion: Clinical Review and Safety
The management of inflammation requires strict adherence to the Two-Week Rule. Any therapeutic regimen must be formally reviewed after 14 days of unsuccessful application. If stagnation persists, further diagnostics—such as assessing local blood flow—are mandatory.
Furthermore, clinical safety must be prioritized regarding specific agents: while OCT is highly effective, manufacturer guidelines specify that its use for wound treatment without medical supervision should not be extended beyond 2 weeks. Resolving the inflammatory bridge is the only viable path to transitioning a stagnant wound back into a productive, healing trajectory.